Evidence map›Paper›PMID 27080086›Full record

ReviewCurrent treatment options in neurology2016

Update on New Daily Persistent Headache.

Hida Nierenburg, Lawrence C Newman

Registry-linked trialAbstract readReview
PubMed Publisher
In one paragraph

Review in Current treatment options in neurology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06018025 (New Daily Persistent Headache), which is not on this map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06018025 completednot on this mapstarted 2024, after this paper: background citation

New Daily Persistent Headache (NDPH): Biomarker Study and Therapy in Children and Adolescents

Typeobservational_patient_registrySponsorDuke UniversityRan2024 to 2025Enrolled38ConditionsNew Persistent Daily HeadacheArmsCGRP antibody
3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Is new daily persistent headache a fallout of somatization? An observational study.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2022
    Observational
  8. Article
  9. New Daily Persistent Headache: a Diagnostic and Therapeutic Odyssey.Current neurology and neuroscience reports · 2019
    Review
  10. Article
  11. Intravenous mannitol in status migrainosus treatment: a clinical case series.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Hida NierenburgMount Sinai West Hospital Center, The Headache Institute, 424 West 59th St. Suite 4A, New York, NY, 10019, USA.
Lawrence C NewmanMount Sinai West Hospital Center, The Headache Institute, 424 West 59th St. Suite 4A, New York, NY, 10019, USA. lnewman@chpnet.org.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

opinion statementNew daily persistent headache (NDPH) is an uncommon and under-recognized primary headache disorder. Clinically, NDPH may resemble migraine or tension-type headache. Unlike migraine or tension-type headaches, however, a distinguishing feature of NDPH is that the majority of patients with NDPH can pinpoint the exact date of onset of symptoms. While cases can arise de novo, in multiple reports, a viral illness precedes the onset of headache. NDPH has two temporal profiles: a self-limited form that resolves spontaneously without treatment and a refractory, persistent form in which headaches continue unabated for years. Diagnosis is predicated on first eliminating secondary mimics via diagnostic imaging and hematological studies. Lumbar puncture should be considered in patients who are refractory to treatment to search for alterations in CSF pressure or for an infectious process. There have been no randomized clinical trials utilizing acute or preventive therapies for NDPH. In clinical practice, treatment is aimed at matching the predominant headache phenotype; nonetheless, most therapies are generally ineffective or only partially effective. Not surprisingly, medication overuse is very common among patients with this disorder and should be identified, although in most patients, eliminating medication overuse does not alter the course of the illness. There have been reports of successful treatment combining doxycycline 100 mg and montelukast 10 mg, dosed BID for 3 months. Anecdotally, in our practice, this combination has occasionally provided good results. Onabotulinum toxin injections are currently under investigation and may provide a potential new effective treatment regimen.

Indexed as

DoxycyclineInternational classification of headache disordersNerve blockadeNew daily persistent headacheOnabotulinum toxin ATreatment

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.